LabDays Copenhagen

Nykode Therapeutics has presented comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.

EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO).

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck’s development portfolio for sleep-wake disorders.

AstraZeneca and Bristol Myers Squibb have held preliminary discussions about a possible merger that would create one of the world’s largest pharmaceutical groups, with a combined value of nearly USD 400 billion, according to reports citing people familiar with the matter (source: Reuters).

Swedish Orphan Biovitrum has announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi.

After an “incredibly difficult time”, the life science industry in the UK is showing clear signs of renewed momentum as venture capital is edging upward and activity across the ecosystem is intensifying.

The Board of Directors has with immediate effect among its members elected Erik Gatenholm to serve as Board Chair of BICO Group AB, until a new Board Chair has been elected by the extraordinary shareholders’ meeting.